

10627140

> d his

(FILE 'HOME' ENTERED AT 15:19:58 ON 23 APR 2004)

FILE 'REGISTRY' ENTERED AT 15:20:11 ON 23 APR 2004

L1 STRUCTURE UPLOADED

L2 6 S L1

L3 138 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:21:29 ON 23 APR 2004

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 15:23:51 ON 23 APR 2004

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 0 S L5 SSS FULL

FILE 'MARPAT' ENTERED AT 15:25:00 ON 23 APR 2004

L8 1 S L3

L9 15 S L3 SSS FULL

L10 14 S L9/COMPLETE

FILE 'CAPLUS' ENTERED AT 15:26:03 ON 23 APR 2004







L11 13 S L10 NOT L4

=>

10627140

=>

Uploading C:\STNEXP4\QUERIES\10627140.str



chain nodes :

1 2 3 5

ring nodes :

6 7 8 9 10 11 12 13 16 17 18 19 20 21 22 26 27 28 29 30

chain bonds :

1-3 1-2 1-26 3-5

ring bonds :

6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17 16-21 16-22 17-18

18-19 19-20 19-22 20-21 26-27 26-30 27-28 28-29 29-30

exact/norm bonds :

1-3 1-2 1-26 3-5 6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17

16-21 16-22 17-18 18-19 19-20 19-22 20-21 26-27 26-30 27-28 28-29 29-30

G1:O,S

G2:[\*1],[\*2]

G3:C,N







Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 26:Atom 27:Atom

28:Atom 29:Atom 30:Atom

10627140









chain nodes :  
 1 2 3 5  
 ring nodes :  
 6 7 8 9 10 11 12 13 16 17 18 19 20 21 22 26 27 28 29 30 32 33  
 34 35  
 chain bonds :  
 1-3 1-2 1-26 3-5  
 ring bonds :  
 6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17 16-21 16-22 17-18  
 18-19 19-20 19-22 20-21 26-27 26-30 27-28 28-29 28-32 29-30 29-35 32-33 33-34 34-35  
 exact/norm bonds :  
 1-3 1-2 1-26 3-5 6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17  
 16-21 16-22 17-18 18-19 19-20 19-22 20-21 26-27 26-30 27-28 29-30  
 normalized bonds :  
 28-29 28-32 29-35 32-33 33-34 34-35

G1:O,S

G2:[\*1],[\*2]

G3:C,N

Match level :  
 1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
 12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 26:Atom 27:Atom  
 28:Atom 29:Atom 30:Atom 32:Atom 33:CLASS 34:CLASS 35:Atom



chain nodes :

1 2 3 5

ring nodes :

6 7 8 9 10 11 12 13 16 17 18 19 20 21 22 26 27 28 29 30 32 33 34 35

chain bonds :

1-3 1-2 1-26 3-5

ring bonds :

6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17 16-21 16-22 17-18 18-19  
19-20 19-22 20-21 26-27 26-30 27-28 28-29 28-32 29-30 29-35 32-33 33-34 34-35

exact/norm bonds :

1-3 1-2 1-26 3-5 6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17 16-21  
16-22 17-18 18-19 19-20 19-22 20-21 26-27 26-30 27-28 29-30

normalized bonds :

28-29 28-32 29-35 32-33 33-34 34-35

G1:O,S

G2:[\*1],[\*2]

G3:C,N


Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 26:Atom  
27:Atom 28:Atom 29:Atom 30:Atom 32:Atom 33:CLASS 34:CLASS 35:Atom

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:120852 CAPLUS  
 DN 140:164061  
 TI Preparation of 1H-pyrazole- and 1H-pyrrole-azabicyclic compounds with  
 nicotinic acetylcholine receptor  $\alpha 7$  ( $\alpha 7$  nAChR) activity  
 IN Piotrowski, David W.; Jacobsen, Eric Jon; Acker, Brad A.; Walker, Daniel  
 P.; Wishka, Donn G.; Groppi, Vincent E., Jr.  
 PA Pharmacia & Upjohn Company, USA  
 SO PCT Int. Appl., 121 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*this appu*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013137	A1	20040212	WO 2003-US19877	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2002-400339P	P	20020801		
OS MARPAT 140:164061				
GI				



AB N-(azabicyclicyl)amides, such as RNR1C(:X)W [R = azabicyclicyl; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; W = N-bonded-substituted-pyrazole or -pyrrole; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the hydrochloride salt of amide I was prepared via a multistep synthetic sequence which concluded with treatment of 4-bromopyrazole with a 20% toluene solution of phosgene in Et acetate followed by addition of (R)-(+)-3-aminoquinuclidine dihydrochloride and Et3N and THF and subsequent treatment with 1 N NaOH to give the desired I.HCl with 25% yield for the final step. The prepared amides were assayed for human  $\alpha 7$ -5HT3 receptor binding activity.

IT 655785-43-6P 655785-97-0P 655785-98-1P  
 655785-99-2P 655786-00-8P 655786-01-9P  
 655786-02-0P 655786-03-1P 655786-04-2P  
 655786-05-3P 655786-06-4P 655786-07-5P  
 655786-08-6P 655786-09-7P 655786-10-0P  
 655786-11-1P 655786-12-2P 655786-13-3P  
 655786-14-4P 655786-15-5P 655786-16-6P

655786-17-7P 655786-18-8P 655786-19-9P  
 655786-20-2P 655786-21-3P 655786-22-4P  
 655786-23-5P 655786-24-6P 655786-25-7P  
 655786-26-8P 655786-27-9P 655786-28-0P  
 655786-29-1P 655786-30-4P 655786-31-5P  
 655786-32-6P 655786-33-7P 655786-34-8P  
 655786-35-9P 655786-36-0P 655786-37-1P  
 655786-38-2P 655786-39-3P 655786-40-6P  
 655786-41-7P 655786-42-8P 655786-43-9P  
 655786-44-0P 655786-45-1P 655786-46-2P  
 655786-47-3P 655786-48-4P 655786-49-5P  
 655786-50-8P 655786-51-9P 655786-52-0P  
 655786-53-1P 655786-54-2P 655786-55-3P  
 655786-56-4P 655786-57-5P 655786-58-6P  
 655786-59-7P 655786-60-0P 655786-61-1P  
 655786-62-2P 655786-63-3P 655786-64-4P  
 655787-11-4P 655787-12-5P 655787-13-6P  
 655787-14-7P 655787-15-8P 655787-16-9P  
 655787-17-0P 655787-18-1P 655787-19-2P  
 655787-20-5P 655787-21-6P 655787-22-7P  
 655787-23-8P 655787-24-9P 655787-25-0P  
 655787-26-1P 655787-27-2P 655787-28-3P  
 655787-29-4P 655787-30-7P 655787-31-8P  
 655787-32-9P 655787-33-0P 655787-34-1P  
 655787-35-2P 655787-36-3P 655787-37-4P  
 655787-38-5P 655787-39-6P 655787-40-9P  
 655787-41-0P 655787-42-1P 655787-43-2P  
 655787-44-3P 655787-45-4P 655787-46-5P  
 655787-47-6P 655787-48-7P 655787-49-8P  
 655787-50-1P 655787-51-2P 655787-52-3P  
 655787-53-4P 655787-54-5P 655787-55-6P  
 655787-56-7P 655787-57-8P 655787-58-9P  
 655787-59-0P 655787-60-3P 655787-61-4P  
 655787-62-5P 655787-63-6P 655787-64-7P  
 655787-65-8P 655787-66-9P 655787-67-0P  
 655787-68-1P 655787-69-2P 655787-70-5P  
 655787-71-6P 655787-72-7P 655787-73-8P  
 655787-74-9P 655787-75-0P 655787-76-1P  
 655787-77-2P 655787-78-3P 655787-79-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 1H-pyrazole- and 1H-pyrrole-azabicyclic amides with  
 nicotinic acetylcholine receptor  $\alpha 7$  activity for therapeutic use  
 in pharmaceutical compns.)

RN 655785-43-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-iodo-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655785-97-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-  
 chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655785-98-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655785-99-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-00-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-01-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655786-02-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(methylthio))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-03-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-thienyl))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-04-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-thienyl))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-05-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-pyridinyl))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10627140



RN 655786-06-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-07-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-08-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-09-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

10627140


Absolute stereochemistry.



RN 655786-10-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-11-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-12-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10627140

RN 655786-13-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-14-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-15-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-16-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655786-17-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-18-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-19-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-20-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-

10627140

chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-21-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-22-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-23-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-24-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655786-25-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-26-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-27-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-28-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655786-29-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-30-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-31-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-4-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-32-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-((1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

10627140


Absolute stereochemistry.



RN 655786-33-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-34-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-35-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10627140

RN 655786-36-0 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-37-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-38-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655786-39-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655786-40-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655786-41-7 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 655786-42-8 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-chloro- (9CI) (CA INDEX NAME)




RN 655786-43-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-bromo- (9CI) (CA INDEX NAME)


10627140




RN 655786-44-0 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-iodo- (9CI)  
(CA INDEX NAME)




RN 655786-45-1 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-methyl- (9CI)  
(CA INDEX NAME)



RN 655786-46-2 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-cyano- (9CI)  
(CA INDEX NAME)




RN 655786-47-3 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(methylthio)- (9CI) (CA INDEX NAME)




RN 655786-48-4 CAPLUS  
CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-thienyl)- (9CI) (CA INDEX NAME)

10627140




RN 655786-49-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-thienyl)-  
(9CI) (CA INDEX NAME)




RN 655786-50-8 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 655786-51-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 655786-52-0 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-phenyl- (9CI)  
(CA INDEX NAME)



10627140


RN 655786-53-1 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 655786-54-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 655786-55-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 655786-56-4 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 655786-57-5 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

10627140




RN 655786-58-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 655786-59-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 655786-60-0 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 655786-61-1 CAPLUS


CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)

10627140




RN 655786-62-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 655786-63-3 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 655786-64-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 655787-11-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655787-12-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-13-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-14-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-15-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 655787-16-9 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-



10627140

(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-17-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-18-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-19-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-20-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10627140

RN 655787-21-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-22-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-23-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-24-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655787-25-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655787-26-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-27-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-28-3 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-29-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10627140

RN 655787-30-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-31-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-32-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-33-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655787-34-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655787-35-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-bromo-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-36-3 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-iodo-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-37-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-  
methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-38-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-cyano-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655787-39-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-

10627140

(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-40-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-41-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-42-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-43-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10627140

RN 655787-44-3 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-45-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-46-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-47-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 655787-48-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10627140



RN 655787-49-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-50-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-51-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-52-3 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 655787-53-4 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-



10627140

methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-54-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-55-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 655787-56-7 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 655787-57-8 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-chloro- (9CI) (CA INDEX NAME)




RN 655787-58-9 CAPLUS

10627140


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-bromo- (9CI)  
(CA INDEX NAME)




RN 655787-59-0 CAPLUS  
CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-iodo- (9CI) (CA INDEX NAME)




RN 655787-60-3 CAPLUS  
CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-methyl- (9CI)  
(CA INDEX NAME)




RN 655787-61-4 CAPLUS  
CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-cyano- (9CI)  
(CA INDEX NAME)



RN 655787-62-5 CAPLUS  
CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(methylthio)- (9CI) (CA INDEX NAME)




RN 655787-63-6 CAPLUS  
CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-thienyl)- (9CI) (CA INDEX NAME)



10627140


RN 655787-64-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-thienyl)-  
(9CI) (CA INDEX NAME)




RN 655787-65-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 655787-66-9 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-pyridinyl)-  
(9CI) (CA INDEX NAME)




RN 655787-67-0 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-phenyl- (9CI)  
(CA INDEX NAME)



RN 655787-68-1 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-fluorophenyl)-  
(9CI) (CA INDEX NAME)



RN 655787-69-2 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)

10627140




RN 655787-70-5 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(4-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 655787-71-6 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 655787-72-7 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-chlorophenyl)-  
(9CI) (CA INDEX NAME)




RN 655787-73-8 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)



RN 655787-74-9 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-methylphenyl)-  
(9CI) (CA INDEX NAME)



RN 655787-75-0 CAPLUS


CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methylphenyl)-  
(9CI) (CA INDEX NAME)

10627140




RN 655787-76-1 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methylphenyl)-  
(9CI) (CA INDEX NAME)




RN 655787-77-2 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 655787-78-3 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 655787-79-4 CAPLUS

CN 1H-Pyrrole-1-carboxamide, N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.51

162.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.69

-0.69

FILE 'REGISTRY' ENTERED AT 15:23:51 ON 23 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10627140

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2004 HIGHEST RN 676437-01-7  
DICTIONARY FILE UPDATES: 21 APR 2004 HIGHEST RN 676437-01-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004







Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10627140a.str



chain nodes :

1 2 3 5

ring nodes :

6 7 8 9 10 11 12 13 16 17 18 19 20 21 22 26 27 28 29 30 32 33  
34 35

chain bonds :

1-3 1-2 1-26 3-5

ring bonds :

6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17 16-21 16-22 17-18  
18-19 19-20 19-22 20-21 26-27 26-30 27-28 28-29 28-32 29-30 29-35 32-33 33-34 34-35

exact/norm bonds :

1-3 1-2 1-26 3-5 6-7 6-10 6-13 7-8 8-9 9-11 9-13 10-12 11-12 16-17

10627140

16-21 16-22 17-18 18-19 19-20 19-22 20-21 26-27 26-30 27-28 29-30  
normalized bonds :  
28-29 28-32 29-35 32-33 33-34 34-35

G1:O,S

G2:[\*1],[\*2]

G3:C,N

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 26:Atom 27:Atom  
28:Atom 29:Atom 30:Atom 32:Atom 33:CLASS 34:CLASS 35:Atom

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 15:24:13 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 32 TO ITERATE

100.0% PROCESSED 32 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 301 TO 979  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 15:24:38 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 609 TO ITERATE

100.0% PROCESSED 609 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L5

=> d his

(FILE 'HOME' ENTERED AT 15:19:58 ON 23 APR 2004)

FILE 'REGISTRY' ENTERED AT 15:20:11 ON 23 APR 2004

L1 STRUCTURE UPLOADED  
L2 6 S L1  
L3 138 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:21:29 ON 23 APR 2004

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 15:23:51 ON 23 APR 2004

L5 STRUCTURE UPLOADED  
L6 0 S L5  
L7 0 S L5 SSS FULL

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.84	318.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'MARPAT' ENTERED AT 15:25:00 ON 23 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 16)(20040416/ED)

10627140

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES  
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6706759 16 MAR 2004  
DE 10335606 11 MAR 2004  
EP 1396268 10 MAR 2004  
JP 2004095205 25 MAR 2004  
WO 2004022766 18 MAR 2004

Structure search limits have been raised. See HELP SLIMIT for the new,  
higher limits.

=> s 13

SAMPLE SEARCH INITIATED 15:25:07 FILE 'MARPAT'  
SAMPLE SCREEN SEARCH COMPLETED - 135 TO ITERATE

100.0% PROCESSED 135 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2006 TO 3394  
PROJECTED ANSWERS: 1 TO 80

L8 1 SEA SSS SAM L1

=> s 13 sss full

FULL SEARCH INITIATED 15:25:22 FILE 'MARPAT'  
FULL SCREEN SEARCH COMPLETED - 3329 TO ITERATE

98.5% PROCESSED 3278 ITERATIONS ( 1 INCOMPLETE) 15 ANSWERS  
100.0% PROCESSED 3329 ITERATIONS ( 1 INCOMPLETE) 15 ANSWERS  
SEARCH TIME: 00.00.28

L9 15 SEA SSS FUL L1

=> s 19/complete

L10 14 L9/COMPLETE

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.14	375.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'CAPLUS' ENTERED AT 15:26:03 ON 23 APR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Apr 2004 VOL 140 ISS 18  
FILE LAST UPDATED: 22 Apr 2004 (20040422/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 110 not 14

14 L10  
L11 13 L10 NOT L4



=&gt; d 1-13 bib abs

L11 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:701861 CAPLUS  
DN **123:111848**  
TI N-(aza heterocycle)carbonyl-substituted indolones useful as serotonergic agents  
IN Becker, Daniel P.; Flynn, Daniel L.; Villamil, Clara I.  
PA G. D. Searle and Co., USA  
SO U.S., 15 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5399562	A	19950321	US 1994-191840	19940204
PRAI	US 1994-191840		19940204		
OS	MARPAT 123:111848				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB This invention relates to indolone compds. of the formula I or a pharmaceutically acceptable salt thereof wherein Z is selected from the group consisting of II-XI; R1 and R2 are independently H, halogen, alkyl, aralkyl, amino, alkoxy, alkylthio, acylamino, hydroxy, nitro, aminocarbonyl, or aminosulfonyl; R3 and R4 are independently H, C1-6 alkyl, or together comprise C2-5 cycloalkyl, optionally substituted by C1-6 alkyl; X = NR5 or O; n is 0, 1 or 2; and R5 is hydrogen or alkyl of one to six carbon atoms which are useful as 5-HT4 agonists or antagonists and 5-HT3 antagonists. Thus, e.g., reaction of endo-3-aminotropane with triphosgene and 1,3-dihydro-3,3-dimethyl-2H-indol-2-one, followed by workup and HCl treatment afforded indolone XII which displayed 5-HT4 agonism in rat TMM (tunica muscularis mucosae) in vitro assay of EC50 = 1214 nM; XII displayed 5-HT3 antagonism of Ki = 4.0 nM.

L11 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1994:655635 CAPLUS  
DN **121:255635**  
TI Preparation of meso-azacyclic aromatic acid amides and esters as serotonergic agents  
IN Becker, Daniel P.; Flynn, Daniel L.; Moorman, Alan E.; Nosal, Roger; Villamil, Clara I.  
PA G.D. Searle and Co., USA  
SO U.S., 11 pp. Cont. of U.S. Ser. No. 666,151, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5318977	A	19940607	US 1992-973090	19921106
	CA 2082415	AA	19920908	CA 1992-2082415	19920304
	US 5612366	A	19970318	US 1994-234336	19940428
	US 5516782	A	19960514	US 1995-443605	19950518
PRAI	US 1991-666151		19910307		
	US 1992-973090		19921106		
	US 1994-234336		19940428		
OS	MARPAT 121:255635				
GI					



AB The title compds. Ar(COX)pZ [p = 1; Ar = Q1; Y = NH; R1 = alkoxy; R2, R3 = H, halo, CF3, etc.; X = NH, O; Z = Q2, etc.; m = 1 or 2; n = 0 or 1; r = 0 or 1] are prepared Treatment of 2-methoxy-4-amino-5-chlorobenzoic acid with 1,1-carbonyldiimidazole, followed by reaction with amine I, gave title compound II. In an in vitro functional assay for serotonin 5-HT4 agonism, II showed an EC50 of 216 nM.

L11 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:213064 CAPLUS

DN 118:213064

TI Preparation of five-membered heterocyclic amide derivatives

IN Goto, Giichi; Kito, Takeshi; Doi, Takayuki

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 18 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04247081	A2	19920903	JP 1991-33518	19910201
PRAI	JP 1991-33518		19910201		

OS MARPAT 118:213064

GI For diagram(s), see printed CA Issue.

AB ACONHB [A = 5-membered heterocyclyl containing optional substituents; B = azabicycloalkyl containing optional substituents], useful as serotonergic antagonists, digestive system regulators, antiemetics, drugs for treating and preventing Alzheimer's disease, etc., are prepared and formulated. To a solution of 0.7 g acid I in DMF were added 1.0 mL Et3N, 0.5 g amine endo-II, and NCP(0)(OET)2 under cooling to give 0.59 g amide endo-III. I showed serotonergic antagonist activity with ID50 of 4.3-9.2 µg/kg i.v. in rats and inhibited cisplatin-induced vomit at 100 µg/kg i.v.

L11 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:22138 CAPLUS

DN 118:22138

TI Preparation of N-(pyrrolizinyllalkyl)benzamides as 5-HT3 antagonists

IN Becker, Daniel P.; Flynn, Daniel L.; Moormann, Alan Edward; Nosal, Roger; Villamil, Clara I.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9215590	A1	19920917	WO 1992-US1525	19920304
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	CA 2082415	AA	19920908	CA 1992-2082415	19920304
	AU 9215786	A1	19921006	AU 1992-15786	19920304
	EP 528026	A1	19930224	EP 1992-908769	19920304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				

10627140

JP 05507942 T2 19931111 JP 1992-508211 19920304  
 EP 504680 A1 19920923 EP 1992-103863 19920306  
 R: PT  
 PRAI US 1991-666151 19910307  
 WO 1992-US1525 19920304  
 OS MARPAT 118:22138  
 GI



AB Title compds. Ar(COX)pZ [p = 0, 1; Ar = Q1, Q2 when p = 0 and Ar = Q3, Q4, etc. when p = 1; Y = NH; R1 = C1-6 alkoxy; R2, R3 = H, halo, CF3, OH, C1-2 alkoxy, C2-7 acyl, (substituted) amino, etc.; R4 = H, halo, C1-6 alkoxy; R13, R14 = H, halo, CF3, C1-6 alkyl, C1-7 acyl, C1-7 acylamino, amino, etc., or R13R14 = methylenedioxy, ethylenedioxy; A1 = O, S, NR12; A3 = N, CH; R12 = H, C1-6 alkyl, aralkyl; X = NH, O; Z = Q5, etc.; n = 0, 1; q = 1, 2] were prepared as 5-HT3 receptor antagonists (no data). Thus, 4-amino-5-chloro-2-methoxybenzoic acid was amidated by tetrahydro-1H-pyrrolizin-7a(5H)-methylamine in DMF in the presence of 1,1'-carbonyldiimidazole to give title compound I in 24% yield.

L11 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:550389 CAPLUS

DN 115:150389

TI 5-HT3 antagonists for treatment of nausea, bradycardia or hypotension associated with myocardial instability

IN Johnson, Edward Stewart; Hamilton, Thomas Conway

PA Beecham Group PLC, UK

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9109593	A2	19910711	WO 1990-GB1996	19901220
	WO 9109593	A3	19910905		
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	ZA 9010219	A	19911127	ZA 1990-10219	19901219
	CA 2071994	AA	19910622	CA 1990-2071994	19901220
	AU 9170516	A1	19910724	AU 1991-70516	19901220
	EP 506813	A1	19921007	EP 1991-901843	19901220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05502872	T2	19930520	JP 1991-502103	19901220
PRAI	GB 1989-28837		19891221		
	WO 1990-GB1996		19901220		
OS	MARPAT 115:150389				

AB 5-HT3 receptor antagonists (Markush given) such as MDL 72222, ICS 205-930, granisetron, PU 46470A, and ondansetron, are effective for treatment and prevention of nausea, bradycardia, and hypotension associated with myocardial

instability. The 5-HT<sub>3</sub> receptor antagonists may be administered orally, parenterally, or topically.

L11 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:565432 CAPLUS

DN 113:165432

TI Azabicyclo derivatives of (hetero)cyclic esters and amides for treatment of serotonin-induced gastrointestinal disorders, and pharmaceutical compositions containing them

IN Buchheit, Karl Heinz

PA Sandoz A.-G., Switz.

SO U.S., 10 pp. Cont. of U.S. Ser. No. 809,541, abandoned.



CODEN: USXXAM

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4910193	A	19900320	US 1987-90986	19870828
PRAI	US 1985-809541		19851216		
OS	MARPAT 113:165432				
GI					



II



Q

AB The title compds., e.g. I or II [Z = CH<sub>2</sub>, O, S, NR<sub>3</sub>; R<sub>1</sub>, R<sub>2</sub> = H, halo, C1-4 alkyl, C1-4 alkoxy, OH, amino, SH, etc.; R<sub>3</sub> = H, C1-4 alkyl, C3-5 alkenyl, Ph, PhCH<sub>2</sub>; B = C(O), SO<sub>2</sub>; C = O, NH; D = Q (n = 2-4; R<sub>8</sub> = C1-7 alkyl, C3-5 alkenyl, PhCH<sub>2</sub>)], or their pharmaceutically acceptable acid addition or quaternary ammonium salts, are provided for treatment of a serotonin-induced gastrointestinal disturbance (gastritis, peptic ulcer, spastic colon, Crohn's disease, etc.). The compds. of the invention preferentially block the low-affinity 5-HT receptors, thereby inhibiting 5-HT-induced contraction, at approx. 10<sup>-7</sup>-10<sup>-9</sup>M. Thus, indole-3-carboxylic acid endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (III) produced a maximal response at 10<sup>-8</sup>M in facilitating field stimulation-induced contractions in muscle strips from different parts of the guinea pig stomach; III was 100-fold more active than metoclopramide. III inhibited 5-hydroxytryptophan-induced gastrointestinal motility with an i.p. ED<sub>50</sub> = 70 µg/kg. A tablet formulation for oral administration contained III 16.9, hydroxypropylcellulose 1.2, corn starch 12.0, lactose 92.8, silica 0.6, and Mg stearate 1.5 mg.

L11 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:178664 CAPLUS

DN 112:178664

TI Preparation of N-[N-(3-tropanyl)carbamoyl]-2,3-dihydroindoles and analogs as 5HT<sub>3</sub> receptor antagonists

IN Joiner, Karen Anne; King, Francis David

PA Beecham Group PLC, UK

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8909217	A1	19891005	WO 1989-GB306	19890322
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4871744	A	19891003	US 1988-202224	19880603
	EP 363466	A1	19900418	EP 1989-904138	19890322
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02503569	T2	19901025	JP 1989-503626	19890322
	US 5049556	A	19910917	US 1989-389286	19890802
	US 5200413	A	19930406	US 1991-740397	19910805
	US 5322951	A	19940621	US 1992-976245	19921113

10627140

PRAI GB 1988-6990 19880323  
 US 1987-550 19870105  
 US 1988-202224 19880603  
 WO 1989-GB306 19890322  
 US 1989-389286 19890802  
 US 1991-740397 19910805  
 OS MARPAT 112:178664  
 GI



AB The title compds. [I; L = NH, O; R1R2 = H, Me; R3 = H, Me, CHMe2; R2R3 = (CH2)4; Z = bicyclic amine groups Q1 - Q3; R4,R5 = alkyl, cycloalkyl, alkenyl, cycloalkylalkyl; n = 2,3; p = 1,2; q, r = 1-3] were prepared. Thus, 2,3-dihydro-2,3-dimethyl-1-indolylcarbonyl chloride (preparation given) was stirred overnight with (endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine in CH2Cl2 to give 35% title compound II which had ID50 of 0.53 µg/kg i.v. for antagonism of the Bezold-Jarisch reflex in rats.

L11 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:172336 CAPLUS

DN 112:172336

TI 5-Hydroxytryptamine receptor antagonists for treatment of cough and bronchoconstriction

IN Williams, Andrew James

PA Beecham Group PLC, UK

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8904660	A1	19890601	WO 1988-GB994	19881114
	W: AU, DK, JP, KR, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8826264	A1	19890614	AU 1988-26264	19881114
	AU 616706	B2	19911107		
	EP 340270	A1	19891108	EP 1988-909596	19881114
	EP 340270	B1	19920715		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02502185	T2	19900719	JP 1988-508864	19881114
	AT 78162	E	19920815	AT 1988-909596	19881114
	US 5098909	A	19920324	US 1989-381666	19890710
	DK 8903458	A	19890712	DK 1989-3458	19890712
PRAI	GB 1987-26716		19871114		
	GB 1987-26717		19871114		
	EP 1988-909596		19881114		
	WO 1988-GB994		19881114		

10627140

OS MARPAT 112:172336

GI



I

AB A method for treatment of cough and/or bronchoconstriction in mammals, including humans, comprises administration of an effective amount of a 5-HT<sub>3</sub> (HT is hydroxytryptamine) receptor antagonist. Pharmaceutical compns. containing the above antagonist and a pharmaceutically acceptable carrier are claimed. The antagonist is XC(O)YZ [X = (un)substituted N-containing heterocyclyl, (un)substituted o-hydroxyaniline, (un)substituted Ph; Y = NH, O; Z = (un)substituted N-containing bicycloalkyl] or I [R<sub>12</sub> = H, C<sub>1</sub>-10 alkyl, C<sub>3</sub>-7 cycloalkyl, Ph, etc.; 1 of R<sub>13</sub>-15 is H, C<sub>1</sub>-6 alkyl, C<sub>3</sub>-7 cycloalkyl, C<sub>2</sub>-6 alkenyl, or Ph-C<sub>1</sub>-3 alkyl and each of the other R<sub>13</sub>-15 = H, C<sub>1</sub>-6 alkyl]. Thus, N-(endo-9-methyl-9-azabicyclo-[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide-HCl, administered i.v. at doses ≤60 µg/kg, blocked capsaicin-induced cough and capsaicin- or SO<sub>2</sub>-induced bronchoconstriction.

L11 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:112094 CAPLUS

DN 112:112094

TI Use of 5-HT<sub>3</sub> antagonists for prevention and treatment of drug dependence

IN Imperato, Assunta; Roemer, Dietmar

PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 8 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3822792	A1	19890119	DE 1988-3822792	19880706
	DE 3822792	C2	19971127		
	EP 302008	A2	19890201	EP 1988-810470	19880707
	EP 302008	A3	19921223		
	R: ES, GR				
	CH 677875	A	19910715	CH 1988-2584	19880707
	DK 8803853	A	19890112	DK 1988-3853	19880708
	FR 2617713	A1	19890113	FR 1988-9350	19880708
	FR 2617713	B1	19940819		
	GB 2206788	A1	19890118	GB 1988-16298	19880708
	GB 2206788	B2	19920325		
	NL 8801733	A	19890201	NL 1988-1733	19880708
	SE 8802570	A	19890328	SE 1988-2570	19880708
	HU 50038	A2	19891228	HU 1988-3610	19880708
	HU 206042	B	19920828		
	AT 401615	B	19961025	AT 1988-1776	19880708
	JP 01031729	A2	19890202	JP 1988-171704	19880709
	AU 8818920	A1	19890112	AU 1988-18920	19880711
	AU 618008	B2	19911212		
	ZA 8804990	A	19900627	ZA 1988-4990	19880711
	BE 1004835	A5	19930209	BE 1988-802	19880711
	US 5039680	A	19910813	US 1990-467598	19900119
	GB 2240475	A1	19910807	GB 1991-4598	19910305
	GB 2240475	B2	19920318		
	GB 2240476	A1	19910807	GB 1991-4599	19910305
	GB 2240476	B2	19920318		
	US 5198459	A	19930330	US 1991-711226	19910606
	AU 9185628	A1	19911205	AU 1991-85628	19911007
	AU 633762	B2	19930204		
	AU 9185630	A1	19911212	AU 1991-85630	19911007
	AU 643075	B2	19931104		
	US 5272168	A	19931221	US 1993-6023	19930115
	US 5519044	A	19960521	US 1993-163218	19931207

PRAI DE 1987-3722959 19870711  
 DE 1987-3735719 19871022  
 CH 1987-4510 19871119  
 DE 1987-3715719 19871022  
 GB 1988-16298 19880708  
 US 1988-217016 19880708  
 US 1990-467598 19900119  
 US 1991-711226 19910606  
 US 1993-6023 19930115

OS MARPAT 112:112094

GI For diagram(s), see printed CA Issue.

AB Serotonergic S3 receptor antagonists ABCD (A = carbo- or heterocyclic residue; B = CO, SO<sub>2</sub>; C = O, NH, bond; D = dialkylamino or mono-, bi-, or tricyclic N compound), their acid addition salts and quaternary ammonium salts, and I (R<sub>1</sub> = H, alkyl, cycloalkyl, alkenyl, Ph, phenylalkyl; 1 of R<sub>2</sub>-R<sub>4</sub> = H, alkyl, cycloalkyl, alkenyl, phenylalkyl; others of R<sub>2</sub>-R<sub>4</sub> = H, alkyl) are useful for prevention or treatment of drug dependence. Thus, the elevation in dopamine level in the rat midbrain ventral tegmental area induced by injection of morphine, EtOH, or nicotine was reversed by injection of endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl indole-3-carboxylate (II). Tablets were prepared containing II 0.500, Na2EDTA.2H<sub>2</sub>O 0.325, Aerosil 200 0.225, lactose 71.076, Mg stearate 0.450, corn starch 11.700, and maleic acid 0.650 mg.

L11 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:55619 CAPLUS

DN 112:55619

TI Arylamido- and arylthioamidoazabicycloalkanes for enhancing memory or correcting memory deficiency

IN Smith, William Levi

PA A. H. Robins Co., Inc., USA

SO Eur. Pat. Appl., 27 pp.


CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 327335	A1	19890809	EP 1989-300961	19890201
	EP 327335	B1	19921014		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4863919	A	19890905	US 1988-150981	19880201
	IL 88434	A1	19920906	IL 1988-88434	19881121
	ZA 8809109	A	19890830	ZA 1988-9109	19881205
	JP 01226818	A2	19890911	JP 1989-13894	19890123
	CA 1320448	A1	19930720	CA 1989-589194	19890126
	DK 8900425	A	19890802	DK 1989-425	19890131
	AU 8929506	A1	19890803	AU 1989-29506	19890201
	AU 629197	B2	19921001		
	AT 81457	E	19921015	AT 1989-300961	19890201
	ES 2045402	T3	19940116	ES 1989-300961	19890201
PRAI	US 1988-150981		19880201		
	EP 1989-300961		19890201		
OS	CASREACT 112:55619; MARPAT 112:55619				
GI					



I



II

AB The title compds. [I; l, m, n, p = 0-3; R1-R4 = H, lower alkyl, Ph; R5 = H, lower alkyl; X = O, S; Ar = (un)substituted Ph, pyridyl, furyl, thienyl, 6-methoxy-1H-benzotriazol-5-yl, 6-methoxy-indol-5-yl, 2-(un)substituted amino-4-methoxypyrimidin-5-yl, 3,4-methylenedioxyphenyl, (un)substituted naphthalenyl, indolyl] useful for the enhancement of memory or the correction of memory deficiency (no data), are prepared. Thus, THF was added to a mixture of 4-amino-5-chloro-2-methoxybenzoic acid and 1,1'-carbonyldimidazole with stirring. When evolution of CO<sub>2</sub> ceased, N was bubbled 1 h through the reaction mixture. A solution of 3-aminoquinuclidine in THF was added to the stirred mixture and stirring at room temperature continued 3 h to give 67% 3-benzamidoquinuclidine derivative (II). A total 46 3-[(hetero)arylamido]quinuclidine including their salts were prepared.

L11 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:400738 CAPLUS

DN 111:738

TI Use of certain 5HT<sub>3</sub> receptor antagonists in the treatment of visceral pain

IN Sanger, Gareth John; Marr, Helen Elizabeth

PA Beecham Group PLC, UK

SO Eur. Pat. Appl., 12 pp.




CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 279512	A2	19880824	EP 1988-300376	19880118
	EP 279512	A3	19920916		
	EP 279512	B1	19960327		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ZA 8800266	A	19881130	ZA 1988-266	19880115
	DK 8800203	A	19880720	DK 1988-203	19880118
	AU 8810355	A1	19880721	AU 1988-10355	19880118
	AU 608276	B2	19910328		
	JP 63215627	A2	19880908	JP 1988-8215	19880118
	JP 2584266	B2	19970226		
	AT 135911	E	19960415	AT 1988-300376	19880118
	ES 2085259	T3	19960601	ES 1988-300376	19880118
	US 4845092	A	19890704	US 1988-145537	19880119
	US 4942160	A	19900717	US 1989-348051	19890505
	US 5063231	A	19911105	US 1990-520108	19900507
PRAI	GB 1987-1022		19870119		
	US 1988-145537		19880119		
	US 1989-348051		19890502		
OS	MARPAT 111:738				
GI					



II

AB 5HT<sub>3</sub> receptor antagonists XCOYZ (I; X = (substituted) indole, indazole,



dihydroindole, indolizine, phenylamino, phenyl; Y = NH, O; Z = R1, R2, R3; n = 2, 3; p, q = 1-3; R12, R13 = Me, Et) or their pharmaceutically acceptable salts are used to manufacture a drug for the treatment of visceral pain. The drugs may be used for treatment of pain due to e.g. irritable bowel syndrome. Twenty minutes after administration at 10 µg/kg i.v. in rats, azabicyclononylindazolylcarboxamide II inhibited the fall in blood pressure due to duodenal distension by 56 ± 8%, and inhibited the fall in intragastric pressure due to the same cause by 74 ± 14%.

L11 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:101830 CAPLUS

DN **110:101830**

TI Use of 5-hydroxytryptamine antagonist heterocyclic derivatives in the treatment of depressions

IN Tyers, Michael Brian

PA Glaxo Group Ltd., UK

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 278173	A2	19880817	EP 1987-311077	19871216
	EP 278173	A3	19891018		
	EP 278173	B1	19931103		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 63277622	A2	19881115	JP 1987-318457	19871216
	US 4973594	A	19901127	US 1987-133896	19871216
	AT 96667	E	19931115	AT 1987-311077	19871216
	US 5071854	A	19911210	US 1989-426860	19891026
	US 5246941	A	19930921	US 1993-5125	19930115
	US 5420139	A	19950530	US 1993-106628	19930816
	US 6221878	B1	20010424	US 1995-402529	19950310
PRAI	GB 1986-30070	A	19861217		
	GB 1986-30072	A	19861217		
	GB 1986-30073	A	19861217		
	GB 1987-7174	A	19870325		
	GB 1987-28140	A	19871202		
	EP 1987-311077	A	19871216		
	US 1987-133896	A3	19871216		
	US 1990-522321	B1	19900511		
	US 1991-723264	B1	19910628		
	US 1992-912337	A3	19920713		
	US 1993-5125	A1	19930115		
	US 1993-106628	A1	19930816		

OS MARPAT 110:101830

AB Antagonists of 5-HT<sub>2</sub> at 5-HT<sub>3</sub> receptors, are drugs for the treatment of depression (no data). These include azabicycloalkyl indolecarboxylates, N-azabicycloalkylamides, imidazole derivs., indole derivs., carbazole derivs, 1αH,3α,5αH-tropan-3-yl benzoates, etc. A tablet contained 3α-tropanyl 1H-indole-3-carboxylate 0.50, CaHPO<sub>4</sub> 87.25, Croscarmellose Na 1.8, Mg stearate 0.45 mg.

L11 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1989:94998 CAPLUS

DN **110:94998**

TI Preparation of indolecarboxylic acid derivatives as 5-HT<sub>3</sub> receptor antagonists

IN King, Francis David; Joiner, Karen Anne

PA Beecham Group PLC, UK

SO Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 287196	A1	19881019	EP 1988-301224	19880215
	EP 287196	B1	19941123		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	US 4920127	A	19900424	US 1988-155756	19880216
	JP 63222169	A2	19880916	JP 1988-34959	19880217
PRAI	GB 1987-3815		19870218		
	GB 1987-12492		19870528		
	GB 1987-18844		19870808		

OS MARPAT 110:94998  
GI



AB The title compds. [I; R = saturated polycyclic amine moiety Q-Q2; R1 = H, Cl, F; R2, R5 = H, Cl-6 alkyl; R2R3, R4R5 = (CH2)2-7, (CH2)mO(CH2)x; R2R5 = bond; R4 = CF3, Cl-7 acyl, Cl-6 alkoxy carbonyl, CO2H, CONH2, (di)alkylcarbamoyl, (un)substituted Cl-6 alkyl, Ph, phenyl-Cl-4 alkyl; R6 = Cl-4 alkyl; Z = NH, O; m, x = 1-5; m + x = 2-6; n = 2, 3; p = 1, 2; q, r = 1-3] and their pharmaceutically acceptable salts were prepared for treating migraine, cluster headache, trigeminal neuralgia, emesis, and visceral pain. Spiro[cyclohexane-1,3'-indolenine] trimer was hydrogenated over Pt oxide to give 32% spiro[cyclohexane-1,3'-indoline] which was treated with COCl2 in PhMe in the presence of Et3N to give 92% spiro[cyclohexane-1,3'-indoline]-3'-carbonyl chloride. To the latter, in CH2Cl2, was added (endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine and Et3N and the mixture was stirred overnight at room temperature to give, after acidification, carboxamide II. In rats II inhibited the 5-hydroxytryptamine-induced Bezold-Jarish reflex with an ED50 of 1.8  $\mu\text{g/kg}$  i.v.